J A Copland

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Pathway signature and cellular differentiation in clear cell renal cell carcinoma
    Han W Tun
    Department of Hematology Oncology, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 5:e10696. 2010
  2. doi request reprint Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers
    Simon J Cooper
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Mol Cancer Ther 11:2105-15. 2012
  3. ncbi request reprint Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography
    John A Copland
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, USA
    Mol Imaging Biol 6:341-9. 2004
  4. ncbi request reprint Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1
    J A Copland
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida 33224, USA
    Oncogene 25:2304-17. 2006
  5. pmc Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial
    R C Smallridge
    Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    J Clin Endocrinol Metab 98:2392-400. 2013
  6. pmc Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma
    S J Cooper
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL 32224, USA
    Oncogene 29:2905-15. 2010
  7. doi request reprint Anaplastic thyroid carcinoma: pathogenesis and emerging therapies
    R C Smallridge
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida 32224, USA
    Clin Oncol (R Coll Radiol) 22:486-97. 2010
  8. pmc Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target
    Laura A Marlow
    Mayo Clinic, Department of Cancer Biology, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    J Clin Endocrinol Metab 95:5338-47. 2010
  9. pmc Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway
    Vitaly Margulis
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:5722-30. 2008
  10. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008

Collaborators

Detail Information

Publications22

  1. pmc Pathway signature and cellular differentiation in clear cell renal cell carcinoma
    Han W Tun
    Department of Hematology Oncology, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 5:e10696. 2010
    ..Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer. The purpose of this study is to define a biological pathway signature and a cellular differentiation program in ccRCC...
  2. doi request reprint Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers
    Simon J Cooper
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Mol Cancer Ther 11:2105-15. 2012
    ..Combinatorial treatment with romidepsin and decitabine in drug resistant tumors is a promising treatment strategy. Moreover, recombinant sFRP1 may be a novel therapeutic strategy for cancers with suppressed sFRP1 expression...
  3. ncbi request reprint Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography
    John A Copland
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, USA
    Mol Imaging Biol 6:341-9. 2004
    ..We have developed a molecular based contrast agent composed of gold nanoparticles conjugated to a monoclonal antibody that improves OAT imaging to potentiate its use in imaging deep tumors in early stages of cancer or metastatic lesions...
  4. ncbi request reprint Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1
    J A Copland
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida 33224, USA
    Oncogene 25:2304-17. 2006
    ..We demonstrated that RS5444, a thiazolidinedione (Tzd) derivative, alone or in combination with paclitaxel, may provide therapeutic benefit to patients diagnosed with ATC...
  5. pmc Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial
    R C Smallridge
    Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    J Clin Endocrinol Metab 98:2392-400. 2013
    ..A phase 1 study was initiated to determine the safety, potential effectiveness, and maximal tolerated dose and recommended phase 2 dose of efatutazone and paclitaxel in anaplastic thyroid cancer...
  6. pmc Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma
    S J Cooper
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL 32224, USA
    Oncogene 29:2905-15. 2010
    ..These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TbetaRIII expression during ccRCC progression...
  7. doi request reprint Anaplastic thyroid carcinoma: pathogenesis and emerging therapies
    R C Smallridge
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida 32224, USA
    Clin Oncol (R Coll Radiol) 22:486-97. 2010
    ..Newer systemic therapies are being tried, and more effective combinations are needed to improve patient outcomes...
  8. pmc Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target
    Laura A Marlow
    Mayo Clinic, Department of Cancer Biology, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    J Clin Endocrinol Metab 95:5338-47. 2010
    ..Up to 42% of human thyroid cancer cell lines are redundant or not of correct tissue origin, and a comprehensive analysis is currently nonexistent. Mechanistically, RhoB has been identified as a novel molecular target for ATC therapy...
  9. pmc Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway
    Vitaly Margulis
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:5722-30. 2008
    ..We evaluated the role of TbetaRIII in mediation of apoptosis using in vitro cell culture and in vivo animal models of clear cell renal cell carcinoma...
  10. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  11. pmc Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta
    Nadine Hempel
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Carcinogenesis 29:905-12. 2008
    ....
  12. ncbi request reprint Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma
    Michelle L Gumz
    Department of Cancer Biology, Mayo Clinic Jacksonville, Florida 32224, USA
    Clin Cancer Res 13:4740-9. 2007
    ..In an effort to gain a better understanding of signaling events in clear cell RCC (cRCC), we investigated the antitumor activity of secreted frizzled-related protein 1 (sFRP1), a negative regulator of Wnt signaling...
  13. ncbi request reprint Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression
    John A Copland
    Internal Medicine Department, University of Texas Medical Branch, Galveston, TX 77555, USA
    Oncogene 22:8053-62. 2003
    ..In addition, these studies unequivocably demonstrate a link between loss of TBR3 and a human disease...
  14. ncbi request reprint Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma
    Alexander Scott Parker
    Department of Urology, Mayo Clinic, Jacksonville, FL 32224, USA
    Hum Pathol 38:453-61. 2007
    ..Data from this investigation are the first to suggest that loss of TbetaRII expression is associated with improved ccRCC patient survival, especially among those patients with less aggressive disease profiles at time of surgery...
  15. ncbi request reprint Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
    Che Leung Law
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer Res 66:2328-37. 2006
    ....
  16. ncbi request reprint High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system
    Mohammad Eghtedari
    Center for Biomedical Engineering, University of Texas Medical Branch, Galveston, Texas 77555 0456, USA
    Nano Lett 7:1914-8. 2007
    ..Our results suggest that LOIS can be used for in vivo detection of gold nanorods at low concentrations and the nanoparticles can be engineered to enhance the diagnostic power of optoacoustic imaging...
  17. ncbi request reprint Potential nonhormonal therapeutics for medical treatment of leiomyomas
    Steven L Young
    Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Semin Reprod Med 22:121-30. 2004
    ..The rationale, evidence, and potential for the use of each of these compounds in the treatment of leiomyomas are discussed...
  18. ncbi request reprint Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice
    Ayman Al-Hendy
    Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Tex, USA
    Am J Obstet Gynecol 191:1621-31. 2004
    ..Leiomyomas (fibroids) are common estrogen-dependent uterine tumors with no effective medicinal treatment; hysterectomy is the mainstay of management...
  19. ncbi request reprint Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity
    Roderick P Regala
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida 32224, USA
    J Biol Chem 280:31109-15. 2005
    ..Our data indicate that PKCiota may be an attractive molecular target for mechanism-based therapies for treatment of lung cancer...
  20. ncbi request reprint Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypothalamic metastases
    John A Copland
    Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA
    Thyroid 16:1293-302. 2006
    ..Molecular characterization of thyroid tumors is rarely applied to patient management. Our aim was to demonstrate the application of molecular and cell biology to patient care...
  21. pmc A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease
    Masahiro Yanagisawa
    Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Biol Chem 283:18344-54. 2008
    ..The data indicate that the increased expression of p120 isoform 1 during tumor progression contributes to the invasive phenotype of cadherin-deficient carcinomas and that the N-terminal domain of p120 is a valid therapeutic target...
  22. ncbi request reprint Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma
    Kevin D Houston
    University of Texas M D Anderson Cancer Center, Science Park Research Division, Smithville, Texas 78957, USA
    Cancer Res 63:1221-7. 2003
    ..These results suggest that in uterine leiomyomas PPARgamma activation is growth inhibitory and that this inhibition is mediated at least in part by negative cross-talk between ER and PPAR signaling pathways...

Research Grants7

  1. TGF Beta receptor biology in human renal cell carcinoma
    JOHN COPLAND; Fiscal Year: 2007
    ..Completion of these studies will define the role of TbetaR3 loss in RCC carcinogenesis, the function of TbetaR3 in normal renal biology and carcinogenesis, and the mechanism of regulation of TbetaR3 in RCC biology. ..
  2. RhoB in cancer pathogenesis and as a target in combinatorial therapy
    ROBERT SMALLRIDGE; Fiscal Year: 2010
    ....
  3. TGF Beta receptor biology in human renal cell carcinoma
    JOHN COPLAND; Fiscal Year: 2009
    ..Completion of these studies will define the role of TbetaR3 loss in RCC carcinogenesis, the function of TbetaR3 in normal renal biology and carcinogenesis, and the mechanism of regulation of TbetaR3 in RCC biology. ..